GlassScriptPhysician profile
Nirav S Shah
NPI 1083970321
$5,406.83
in general payments reported to CMS, 2019-2025
35 companies · $563 in 2025
The $563 reported for 2025 was more than what 91% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $813 · 2020: $481 · 2021: $330 · 2022: $1,516 · 2023: $754 · 2024: $950 · 2025: $563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,266.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spinal Simplicity, LLC | $1,239.69 | 2022-2025 | Ha Minuteman G3-R |
| Abbott Laboratories | $1,114.51 | 2019-2025 | Proclaim, Eterna |
| Boston Scientific Corporation | $634.89 | 2019-2025 | Intracept, Superion Indirect Decompression System |
| Painteq LLC | $359.23 | 2021-2024 | Painteq |
| Vertos Medical, INC. | $265.72 | 2019-2024 | Mild Device Kit |
| Bioness INC | $168.92 | 2020 | |
| Abbvie INC. | $167.59 | 2023-2025 | Botox, Qulipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $164.31 | 2019-2025 | Relistor, Trulance |
| Medtronic, INC. | $159.14 | 2022-2025 | Intellis Adaptivestim, Inceptiv |
| Nevro Corp. | $155.82 | 2023 | Senza |
| Scilex Pharmaceuticals INC. | $105.97 | 2019-2023 | Ztlido |
| Nalu Medical, INC. | $105.65 | 2022-2025 | Nalu Neurostimulation System |
| Collegium Pharmaceutical, INC. | $85.83 | 2019-2021 | |
| Ibsa Pharma INC. | $79.50 | 2023 | Tirosint, Licart |
| Saluda Medical Americas, INC. | $73.91 | 2023-2025 | Evoke Scs, Evoke |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $61.19 | 2025 | |
| Biotronik Nro, INC. | $56.47 | 2025 | Prospera |
| Pfizer INC. | $50.46 | 2019-2020 | |
| Stimwave Technologies Incorporated | $47.50 | 2019-2021 | |
| Spr Therapeutics, INC | $46.34 | 2023-2024 | Sprint Pns System |
| Shionogi INC | $28.21 | 2019 | |
| Stryker Corporation | $27.43 | 2025 | Mild Device Kit |
| Pacira Pharmaceuticals Incorporated | $23.50 | 2019 | |
| Valinor Pharma, LLC | $22.14 | 2023 | Movantik |
| Ultragenyx Pharmaceutical INC. | $21.66 | 2022 | |
| Amgen INC. | $20.58 | 2019 | |
| Foundation Fusion Solutions, LLC | $18.27 | 2023 | |
| Relievant Medsystems, INC. | $17.35 | 2022 | |
| Novartis Pharmaceuticals Corporation | $15.36 | 2019 | |
| Biodelivery Sciences International, INC. | $15.31 | 2019 | |
| Bioventus LLC | $15.24 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.43 | 2021 | |
| Medtronic USA, INC. | $13.17 | 2020 | |
| Kaleo, INC. | $12.54 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nirav Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.